ASND | Ascendis pharma a/s - Stock Value & PE Ratio Analysis

3

24

15

Limited Growth

AI analysis rates ASND with a lower value score of 2.
It is mainly due to unstable operating cash flow, along with potential value may be lower.
Over the past 3 months, ASND has maintained a consecutive value rating of 2.0, close to the rating of 2.4 over the past 3 years, indicating low growth opportunities for enterprise value.
Compared to all stocks in the Health Care sector, ASND has a medium value rating.

ASND Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/05/04 (Weekly Update)

ASND Financial Forecast

Unit : USD

Update to 2025/5/9 (Quarterly Update)

ASND Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	-1.66	33.1%	6.4%	110.67M	1,365.3%	-27.7%	-22.1%
2024Q2	-1.89	11.7%	26.8%	67.9M	1,122.9%	-8.4%	-303.9%
2024Q1	-2.05	-18.5%	33.1%	38.71M	2,896.2%	3%	-136.6%
2022Q3	-3.78	-25.6%	51.2%	24.66M	1,934%	175.3%	-1,105%
2021Q4	-2.48	-75.9%	10.2%	7.55M	760.8%	23.6%	-2,165.9%

Update to 2025/5/9 (Quarterly Update)

ASND Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

ASND Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of ASND from 2015/03 till Now

-31.93%
Cumulative Return: -3.72%
Annual Return: 20.86%
Volatility: -0.18
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from March, 2015 to May, 2025. (Total Trades: 2)